Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage biopharmaceutical company focused on the PI3 kinase pathway in oncology and inflammatory disease, closed a $30M Series B financing. Participants include Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners.

XORI (Seattle, WA) a development-stage company focused on a technology for the rapid discovery and development of therapeutic monoclonal antibodies for oncology, immune disorders and infectious disease, closed a $3M Series A financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, and WRF Capital.
*value was undisclosed

MolecularMD (Portland, OR) a molecular diagnostics company specializing in genomic assays to measure patient response and resistance to targeted cancer therapies focused on Chronic myelogenous leukemia, closed a $3M Series A financing. Participants include Ballast Point Ventures.

Qwell Pharmaceuticals (Seattle, WA) a stealthy start-up biotechnology company devoted to small-molecule development primarily for oncology indications, closed a $7M Series A financing. Participants include Arch Venture Partners and Wellcome Trust.

Healionics (Redmond, WA) an early-stage biomaterial surface coating and tissue regeneration company closed a $2.6M Series B financing. Participants include Bellingham Angels, Alliance of Angels, Keiretsu, Tacoma Angel Network and Zino Society.

Cocrystal Discovery (Seattle, WA) developer of antiviral therapeutics for the treatment of serious and chronic viral diseases, closed a $10M Series A financing. Participants include The Frost Group.

Light Sciences Oncology (Bellevue, WA) clinical-stage developer of a light-activated drug product to treat patients with solid tumor cancers, closed $40M Series C. Participants include Essex Woodlands Health Ventures, SLS Venture, Adams Street Partners, Novo Ventures and New Enterprise Associates.

PhysioSonics (Seattle, WA) a developer of noninvasive neurologic products, closed a $4M Series A financing. Participants include Johnson & Johnson Development Corp.

Immune Design (Seattle, WA) vaccine developer focused on regulating immune responses by targeting dendritic cell biology with combinations of proprietary vectors and adjuvants, closed a $18M Series A financing. Participants include Alta Partners, The Column Group and Versant Ventures.

Seattle Medical Technologies (Seattle, Washington) medical device company focused on diabetes, closed a $21M Series B financing. Participants include Canaan Partners, Skyline Venture Partners, Frazier Healthcare Ventures and Three Arch Partners.

Ekos Corp. (Bothell, WA) developer of drug delivery catheters leveraging ultrasound technology for peripheral arterial occlusions and administration of contrast media, closed a $5M Series C financing. Participants include ARCH Venture Partners, Bessemer Venture Partners, Merrill Lynch, Mitsui & Co., Spray Venture Partners, MedVenture Associates, Protostar, Technology Partners and Morgan Stanley Venture Partners.

PhaseRx  (Seattle, WA) an early-stage siRNA therapeutic company closed  a $19M Series A financing. Participants include 5AM Ventures, Arch Venture Partners and Versant Ventures.

Alder Biopharma (Bothell, WA) developer of unique antibody technologies that may increase antibody potency, accelerate production cycles, and lower production costs closed a $40M Series C financing. Participants include Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.